方盛製藥(603998.SH)：佰駿醫療引入DaVita為戰投
格隆匯5月24日丨方盛製藥(603998.SH)公佈，公司控股子公司湖南省佰駿高科醫療投資管理有限公司(簡稱“佰駿醫療”)擬引入腎科領域保健服務提供商DaVita Inc.(紐約證券交易所上市，股票代碼：DVA)之間接控股子公司DaVita China Pte Ltd.(簡稱“德維特公司”)為戰略投資者。
2021年5月22日，公司召開第五屆董事會2021年第五次臨時會議，審議並通過了《關於轉讓控股子公司部分股權暨引進戰略投資者的議案》，同意公司將佰駿醫療31.70%股權轉讓給德維特公司，轉讓對價為人民幣1.47億元；同時，擬將公司持有的佰駿醫療5.10%股權轉讓予佰駿醫療員工持股平台(該平台為佰駿醫療實施員工股權激勵的持股平台)；同意佰駿醫療以新主體向德維特公司借款4.50億元人民幣。
完成該次交易後，德維特公司、康萊健康、方盛製藥、員工持股平台分別持有佰駿醫療31.70%、44.10%、14.20%、10%股權。
佰駿醫療成立於2014年12月，是一家專業投資腎病專科醫院的投資公司，致力於以腎病專科業務為主的醫院投資與運營，已經形成以血液透析為核心業務，以中醫藥服務、慢性腎病及併發症管理、腎移植病人後期管理、透析病人的飲食和康復服務等為輔的運作模式。佰駿醫療旗下已擁有12家連鎖醫院、血液淨化中心10個，擁有透析設備近400台，員工近1500人，服務透析患者逾2000人，現有編制牀位1400多張(已有牀位數逾1100張)。
公司表示，Davita Inc作為全球領先的腎科領域保健服務提供商，戰略入股佰駿醫療後，將為其在腎病治療及健康管理等方面帶來先進的管理理念和技術，有利於提升其綜合競爭實力。此外，該次將通過老股轉讓的方式推出員工持股/激勵方案，有利於更好地推動佰駿醫療的可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
